Jefferies Financial Group Inc. Purchases Shares of 293,670 Xeris Biopharma Holdings, Inc. $XERS

Jefferies Financial Group Inc. acquired a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 293,670 shares of the company’s stock, valued at approximately $2,326,000. Jefferies Financial Group Inc. owned approximately 0.16% of Xeris Biopharma at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Royal Bank of Canada grew its holdings in shares of Xeris Biopharma by 1,411.2% in the first quarter. Royal Bank of Canada now owns 213,084 shares of the company’s stock valued at $1,170,000 after purchasing an additional 198,984 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Xeris Biopharma by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock valued at $461,000 after purchasing an additional 3,594 shares in the last quarter. Millennium Management LLC raised its stake in Xeris Biopharma by 19.0% during the first quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock valued at $12,726,000 after purchasing an additional 369,420 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in Xeris Biopharma by 75.4% during the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock valued at $15,317,000 after purchasing an additional 1,199,435 shares during the last quarter. Finally, Caxton Associates LLP bought a new position in Xeris Biopharma during the first quarter valued at $170,000. 42.75% of the stock is currently owned by institutional investors.

Insider Transactions at Xeris Biopharma

In related news, Director John Johnson sold 15,000 shares of the stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $6.09, for a total value of $91,350.00. Following the transaction, the director owned 683,083 shares of the company’s stock, valued at $4,159,975.47. This represents a 2.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Beth Hecht sold 16,666 shares of the firm’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $8.01, for a total value of $133,494.66. Following the transaction, the insider owned 1,144,462 shares in the company, valued at $9,167,140.62. The trade was a 1.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 271,499 shares of company stock valued at $2,038,917 in the last ninety days. Corporate insiders own 4.35% of the company’s stock.

Wall Street Analyst Weigh In

XERS has been the topic of a number of research reports. Barclays boosted their target price on shares of Xeris Biopharma from $9.00 to $12.00 and gave the stock an “overweight” rating in a report on Thursday, August 20th. Weiss Ratings cut Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Finally, Wall Street Zen downgraded Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $12.00.

Xeris Biopharma Trading Down 1.4%

XERS stock opened at $8.48 on Friday. Xeris Biopharma Holdings, Inc. has a twelve month low of $5.25 and a twelve month high of $10.08. The stock has a market capitalization of $1.55 billion, a price-to-earnings ratio of -77.09 and a beta of 0.66. The company has a quick ratio of 1.02, a current ratio of 1.45 and a debt-to-equity ratio of 17.00. The firm’s fifty day simple moving average is $8.29 and its two-hundred day simple moving average is $6.93.

Xeris Biopharma (NASDAQ:XERS) last released its earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.19). Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%.The firm had revenue of $92.10 million during the quarter, compared to the consensus estimate of $90.12 million. As a group, analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current year.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.